Last updated on July 2010

Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation


Brief description of study

There is a significant (50-80%) risk of acute graft-versus-host disease(GVHD) and early mortality (30%) associated with high risk stem cell transplantation (SCT) such as that from a matched unrelated donor or HLA-mismatch sibling. Mycophenolate mofetil (MMF) has been shown to be an effective and safe immunosuppressant in the prevention and treatment of rejection after solid organ transplantation. Its role in acute GVHD prophylaxis in high risk SCT will be investigated in this clinical trial.

Clinical Study Identifier: NCT00563589

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Winnie WW Cheung, Dr

Queen Mary Hospital
Hong Kong, China
  Connect »